News & Updates

Show Multimedia Only
4 anti-obesity meds: AGA top picks

4 anti-obesity meds: AGA top picks

01 Nov 2022 byElvira Manzano

Obese adults with weight-related complications who do not respond adequately to lifestyle interventions should be offered one of four anti-obesity medications, according to the new clinical practice guideline on pharmacological interventions released by the American Gastroenterological Association (AGA).

4 anti-obesity meds: AGA top picks

01 Nov 2022
Nelonemdaz safe but fails to improve outcomes in stroke

Nelonemdaz safe but fails to improve outcomes in stroke

01 Nov 2022

Treatment with nelonemdaz, a multitarget neuroprotectant that selectively blocks N-methyl-D-aspartate receptors and scavenges free radicals, does not appear to significantly improve stroke outcomes as compared with placebo, although nelonemdaz-treated patients show a greater tendency toward achieving modified Rankin Scale scores of 0–2 at 12 weeks, according to the results of a phase II study.

Nelonemdaz safe but fails to improve outcomes in stroke

01 Nov 2022
Extending letrozole treatment beyond 5 days induces ovulation in certain PCOS patients

Extending letrozole treatment beyond 5 days induces ovulation in certain PCOS patients

31 Oct 2022 byJairia Dela Cruz

For women with polycystic ovary syndrome (PCOS), if a 5-day letrozole regimen for ovulation induction does not work, extending the duration of treatment may do the job, as shown in a study.

Extending letrozole treatment beyond 5 days induces ovulation in certain PCOS patients

31 Oct 2022
CHD tied to better prognosis in infective endocarditis

CHD tied to better prognosis in infective endocarditis

31 Oct 2022

Among patients with infective endocarditis (IE), the presence of congenital heart disease (CHD) appears to be correlated with better short- and long-term outcomes, a new study has found.

CHD tied to better prognosis in infective endocarditis

31 Oct 2022